Contact Us
Drug Search Results
More Filters [+]

BI-764532

Alternative Names: bi-764532, bi 764532, bi764532
Latest Update: 2024-08-27
Latest Update Note: News Article

Product Description

Boehringer Ingelheim is developing BI-764532 as a treatment for Patients With Small Cell Lung Carcinoma and Other Neoplasms. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04429087)

Mechanisms of Action: DLL3 Inhibitor,CD3 Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: Intravenous

FDA Designation:
Fast Track - Large Cell Carcinoma|Neuroendocrine Carcinoma
Fast Track - Lung Cancer|Small Cell Lung Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BI-764532

Countries in Clinic: Belgium, Bulgaria, China, France, Germany, Italy, Japan, Korea, Netherlands, Poland, Portugal, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 14

Highest Development Phases

Phase 2: Large Cell Carcinoma|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Small Cell Lung Cancer

Phase 1: Glioma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
U1111-1290-7234

P1

Recruiting

Glioma

2026-08-17

jRCT2031230615

P1

Not yet recruiting

Small Cell Lung Cancer

2026-06-30

NCT05963867

P1

Recruiting

Neuroendocrine Carcinoma|Neuroendocrine Tumors|Small Cell Lung Cancer

2026-01-18

28%
DAREON™-7

P1

Recruiting

Neuroendocrine Tumors

2025-11-05

Recent News Events

Date

Type

Title

08/27/2024

News Article

 Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio

08/27/2024

News Article

 Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio

11/29/2023

News Article

 Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung

10/03/2023

News Article

 Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions